Sciety’s portfolio consists of companies that develop and commercialise solutions based on vital innovations. These range from personalised treatments for serious diseases to blood-based diagnostics for early cancer detection, and digital tools that support emergency care and surgery.
We focus on companies with scalable solutions to medical challenges where there is a clear clinical need and strong commercial potential. We also invest in companies developing research and development tools that can accelerate medical breakthroughs and create significant value for society.
PeptiSystems has developed a groundbreaking technology for the large-scale production of precision drugs. The company sells instruments for manufacturing peptides and oligonucleotides used in pharmaceutical manufacturing.
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.
NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
Pharmability (fd TIRmed) is developing the next generation of treatment for atopic dermatitis (eczema). With advanced targeted therapy, the company’s treatment targets the root causes of the disease, aiming to provide effective and long-lasting relief.
Hälsa Hemma has developed a hybrid and scalable healthcare platform that combines digital consultations with home visits. With an established patient base, Hälsa Hemma provides care that is efficient, accessible, and highly appreciated by patients.
Each year, more than 10 million people suffer from tuberculosis. EMPE has developed a patented quick test for the diagnosis of tuberculosis adapted to clinics with limited resources.
The company has developed a DNA sequencing solution with significantly improved performance compared with current alternatives. The market is growing rapidly in terms of both research and clinical applications.
Evidence has developed a unique SaaS solution with AI functionality, specifically designed for healthcare. Evidence helps management optimize resource use and improve care quality by consolidating all critical functions into a single system.
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
SAGA Diagnostics develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment. The tests are based on the company’s proprietary technologies for analyzing circulating tumor DNA (ctDNA).
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Learning to Sleep is a digital sleep clinic. The company offers an evidence-based treatment that uniquely combines support from a sleep coach with digital aids.
Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.
Raytelligence has developed a unique, non-intrusive radar sensor and cloud platform for monitoring vital signs, such as respiration, heartbeat and position and movement. The company focuses on elderly care in the home.
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
